Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
HMPL-A251 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| HMPL-A251 | DRUG | Six dose cohorts are planned for the Dose Escalation phase; at least three participants with solid tumors will be enrolled in each dose cohort. Bayesian optimal interval design with backfill (BF-BOIN, Zhao, 2023) will be used to guide dose escalation and determine the MTD and/or RDE of HMPL-A251. All study participants will receive HMPL-A251 as IV infusion until PD, intolerable toxicity, or other protocol-specified criteria for ending study treatment, whichever occurs first. |
HMPL-A251 is an investigational small molecule being developed by HUTCHMED (China) Limited for the treatment of advanced or metastatic HER2-expressing solid tumors in adults. It is currently in Phase 2 clinical development and has not been approved by the FDA. It is being studied in a biomarker-selected patient population.
HMPL-A251 is being evaluated for the treatment of adult patients with advanced or metastatic HER2-expressing solid tumors. It is an investigational therapy and is not approved for any indication. Its use is currently limited to clinical trial participation in a biomarker-selected population.
HMPL-A251 targets EGFR, a protein receptor. It is a small molecule directed at this target and is being studied in patients with HER2-expressing solid tumors. The trial enrolls a biomarker-selected population, meaning participants are chosen based on specific molecular characteristics of their tumors.
HMPL-A251 is being developed by HUTCHMED (China) Limited, which trades under the ticker HCM. The company is running the clinical program for this small molecule in adult patients with advanced or metastatic HER2-expressing solid tumors.
HMPL-A251 is in Phase 2 clinical development. It is an investigational drug and has not received FDA approval. The ongoing study is a Phase 1/2a trial, and the asset is currently listed as being in Phase 2 overall.
HMPL-A251 is being studied in the Phase 1/2a trial NCT07228247, titled a study of HMPL-A251 in participants with advanced or metastatic HER2-expressing solid tumors. The trial is currently recruiting, is uncontrolled, and has a planned enrollment of 147 participants.